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Background: Emerging evidence has suggested that dysregulation of miR-182-5p may contribute to tumor
development and progression in several types of human cancers. However, its role in renal cell carcinoma (RCC) is
still unknown.
Methods: Quantitative RT-PCR was used to quantify miR-182-5p expression in RCC clinical tissues. Bisulfite sequencing
PCR was used for DNA methylation analysis. The CCK-8, colony formation, flow cytometry, and a xenograft model were
performed. Immunohistochemistry was conducted using the peroxidase and DAB methods. A miR-182-5p target was
determined by luciferase reporter assays, quantitative RT-PCR, and Western blotting.
Results: miR-182-5p is frequently down-regulated in human RCC tissues. Epigenetic modulation may be involved in
the regulation of miR-182-5p expression. Enforced expression of miR-182-5p in RCC cells significantly inhibited the
proliferation and tumorigenicity in vitro and in vivo. Additionally, overexpression of miR-182-5p induced G1-phase arrest
via inhibition of AKT/FOXO3a signaling. Moreover, FLOT1 was confirmed as a target of miR-182-5p. Silencing FLOT1 by
small interfering RNAs phenocopied the effects of miR-182-5p overexpression, whereas restoration of FLOT1 in
miR-182-5p -overexpressed RCC cells partly reversed the suppressive effects of miR-182-5p.
Conclusions: These findings highlight an important role for miR-182-5p in the pathogenesis of RCC, and restoration of
miR-182-5p could be considered as a potential therapeutic strategy for RCC therapy.
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Renal cell carcinoma (RCC) is the most common type of
adult kidney cancer, and clear cell RCC represents the
most common renal cancer histology. The incidence and
mortality rates of kidney cancer have increased in recent
years, with an expected 271,000 newly-diagnosed cases and
116,000 deaths in 2008 worldwide [1]. About one-third of
RCC patients are diagnosed with metastatic disease and up
to 50% of patients develop metastatic disease [2] with a very
poor prognosis because of the refractory nature of RCC to
the current treatment regimens [3]. Therefore, it is crucial
to identify novel therapeutic targets, including non-coding* Correspondence: zheng_xy@zju.edu.cn; xielp@zju.edu.cn
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unless otherwise stated.RNAs (ncRNA) in RCC, to develop more effective treat-
ment options for this fatal disease.
MicroRNAs (miRNAs) are a class of small, endogenous,
noncoding RNAs that are approximately 22 nucleotides in
length and make up a novel class of gene regulators [4]. It
has been firmly established that miRNAs regulate various
cellular processes such as cellular differentiation, develop-
ment, proliferation, apoptosis and metabolism [5,6]. Recent
evidence indicates that the aberrant regulation of miRNAs
plays an important role in RCC pathogenesis. Several stud-
ies profiling miRNA expression in RCC have identified a
number of differentially expressed miRNAs though no con-
sensus has been reached [7-11]. In addition, a series of miR-
NAs (including miR-34a, miR-145, miR-205, miR-708,
miR-1285 and miR-1826) have been shown to modulateThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cells [12-17].
MicroRNA-182-5p is a member of the miR-183 family
which includes miR-96, miR-182 and miR-183. These
miRNAs are coordinately expressed from a single genetic
locus located at human chromosome 7q32.2. Most previ-
ous studies suggested an oncogenic role for miR-182-5p
in various types of human cancers, including prostate
cancer, breast cancer, bladder cancer, liver cancer, colon
cancer, cervical cancer, ovarian cancer, and glioma [18-25].
However, three studies illustrated that the ectopic expres-
sion of miR-182-5p inhibits the cell growth of posterior
uveal melanoma, lung cancer and stomach cancer by
targeting MITF, BCL2, cyclin D2, RGS17 and CREB1
[26-28]. Therefore, defining the function of miR-182-5p is
complicated because it can be an oncogene or a tumor
suppressor in the context of different cancers. To the best
of our knowledge, the biological function of miR-182-5p
in RCC is not yet well understood. In this study we
observed the frequent downregulation of miR-182-5p in
human RCC tissues. In addition, for the first time, we
found that miR-182-5p could suppress the proliferation
and tumorigenicity of RCC cells by targeting FLOT1.
Results
miR-182-5p is down-regulated in RCC
As indicated by the previous published datasets, miR-182-
5p was in a down-regulated expression pattern in RCC
compared with normal renal tissue [29,30]. To further
validate the expression pattern of miR-182-5p in RCC, we
quantified the expression levels of miR-182-5p in 25 pairs
of human RCC tissues and adjacent non-tumor tissues by
qRT-PCR (Figure 1A). The relative expression of miR-
182-5p was normalized to an endogenous control (U6
RNA). The results showed that the expression level of
miR-182-5p was generally lower in tumor tissues com-
pared to matched non-tumor tissues (19 out of 25
exhibited a down-regulated pattern). Thus, we specu-
lated that miR-182-5p might be a putative tumor sup-
pressor in RCC.
Cancer-specific methylation pattern of CpG islands
associated with miR-182-5p in RCC cells
Transcriptional regulation plays a crucial role in miRNA
expression. We first predicted the presence of CpG islands
in the upstream sequence of pri-miR-182. The miRStart
database [31] (http://mirstart.mbc.nctu.edu.tw/home.php)
predicted that the transcription start site (TSS) of miR-
182-5p may be located 9729 upstream of the precursor.
Then, the CpG Island Searcher program (http://www.
urogene.org/methprimer/) helped us to identify a prom-
inent CpG island located 8–10 kb upstream of miR-182
(Figure 1B). Liu et al. previously reported that this CpG
island was exclusively methylated in melanoma cellsand may be involved in the regulation of miR-182 ex-
pression [32]. To clarify the possible roles of the
epigenetic mechanism of miR-182-5p silencing in RCC
cell lines, we treated 786-O and Caki-1 with 5-Aza, a
methyltransferase inhibitor. We found that the treatment
of cells with 5-Aza significantly elevated the expression of
miR-182-5p in both cell lines (Figure 1C), indicating the
existence of epigenetic regulation.
We next conducted sodium bisulfite sequencing assay to
evaluate the methylation status of the predicted CpG
island. The results illustrated that the methylation levels
were significantly higher in RCC cell lines (786-O and
Caki-1) and tissues, compared with para-cancer normal
kidney tissues (Figure 1D and E). While 95.5% and 98.5%
of CpGs were methylated in 786-O and Caki-1 cells,
respectively, only 9.9% and 10.2% of CpGs were methyl-
ated in normal samples 1 and 2. The methylation levels of
tumor samples 1 and 2 (26.1% and 20.8%, respectively)
were relatively low compared with 786-O and Caki-1 cells.
Moreover, the treatment of cells with 5-Aza apparently re-
duced the methylation level of this CpG island (Additional
file 1: Figure S1), which further indicated that this epigen-
etic modulation could be involved in the regulation of
miR-182-5p expression.
Overexpression of miR-182-5p inhibits the proliferation
and tumorigenicity of RCC cells in vitro and in vivo
We transfected the RCC cell lines 786-O and Caki-1
with miR-182-5p mimics and examined the effects on
cellular proliferation. The ectopic expression of miR-
182-5p was confirmed by qRT-PCR (Additional file 2:
Figure S2). CCK-8 and colony formation assays revealed
that the overexpression of miR-182-5p significantly de-
creased the growth rate of both RCC cell lines, compared
to NC-transfected cells (Figure 2A and B). To further
confirm the above findings, the growth rates of Caki-1
cells with or without miR-182-5p over-expression were
examined after s.c. implantation into BALB/c mice. The
over-expression of miR-182-5p resulted in a dramatic
retardation of tumor growth in vivo (Figure 2C and D).
IHC staining confirmed that the tumors derived from the
miR-182-overexpressing cells displayed much lower Ki-67
indices than the tumors from the control group (Figure 2E).
Taken together, these results showed that miR-182-5p
negatively modulate RCC cells growth.
Upregulation of miR-182-5p in RCC cells triggers G1-phase
arrest and regulates cell cycle factors through AKT/FOXO3a
signaling
The underlying mechanism for miR-182-5p-suppressed
tumor growth was further explored with FACS. We ob-
served a significant increase in the percentage of cells
in the G1/G0 phase and a decrease in the percentage of
cells in the S phase in miR-182-5p-overexpressing cells
Figure 1 miR-182-5p is down-regulated in RCC and regulated by DNA methylation. (A) The relative expression levels of miR-182-5p in
individual 25 pairs of RCC tissues were presented as the fold change of miR-182-5p referred to the corresponding normal tissues. (B) The regions
analyzed by BSP are indicated. (C) DNA methylation inhibitor 5-aza-dC stimulated the expression of miR-182-5p compared with DMSO treated
samples. Error bars represent the S.D. from three independent experiments. (D) and (E) The promoter of miR-182-5p was hypermethylated in RCC
cell lines and tissues. The open and filled circles represent the unmethylated and methylated CpGs, respectively. Error bars represent the S.D. from
eight randomly chosen colonies. ***P < 0.001; **P < 0.01; *P < 0.05.
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phenomenon, the G1/S transition regulators CCND1
and CDK4 were significantly decreased at the protein
and mRNA levels in miR-182-5p-overexpressing cells
(Figure 3B, 3D and Additional file 3: Figure S3). p-Rb
and E2F1, the major downstream effector proteins of
cell cycle signaling, also showed obvious changes in ex-
pression (Figure 3B and Additional file 3: Figure S3). It
has been well documented that the expression of CCND1
can be transcriptionally regulated by FOXO3a [33] and, in
turn, the transcriptional activity of FOXO3a is modulated
by AKT phosphorylation [34,35]. To further confirm that
FOXO3a is a downstream target of AKT phosphorylation
in RCC cells, we found that a small molecule inhibitor of
AKT (LY294002) could significantly activate FOXO3a
(Additional file 4: Figure S4). Thus, we hypothesized thatthe upregulation of miR-182-5p might inhibit AKT/
FOXO3a signaling. As shown in Figure 3B and Additional
file 3: Figure S3, the phosphorylation levels of both
FOXO3a and AKT decreased in miR-182-5p-overex-
pressing RCC cells. In addition, FOXO3a activity was
strongly activated by the upregulation of miR-182-5p,
as demonstrated by a FOXO3a luciferase reporter vec-
tor (Figure 3C).
miR-182-5p downregulates FLOT1 expression by directly
targeting its 3′UTR
A miRNA usually performs its function by reducing the
expression of target genes. Thus our next aim was to
investigate the targets of miR-182-5p that contributed
to its anti- proliferation function. FLOT1, a putative
target of miR-182-5p identified by TargetScan, was of
Figure 2 Effect of miR-182-5p in regulating RCC cells proliferation. (A) CCK-8 assay. The relative cell viability of the miR-182-5 transfected
group was significantly lower than that of NC transfected. (B) Colony formation assay (Representative wells were presented). The colony formation
rate was significantly lower for miR-182-5p treated group compared with NC treated group. Error bars represent the S.D. from three independent
experiments. (C), (D) and (E) Tumor xenograft model. The tumor volumes and the growth curves indicated that tumor in miR-182-5p group was
in a significant slower growth pattern. Decreased Ki-67 expression was also detected in miR-182-5p treated tumors. Error bars represent the S.D.
from five nude mice. *P < 0.05.
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predicted binding sites and was previously considered
as a positive cell cycle regulator in breast cancer [36].
In our current study, we revealed that FLOT1 was com-
monly over-expressed in all three types of renal cell
cancer tissues (Figure 4A and Additional file 5: Figure
S5). With qRT-PCR and western blot, we verified that
FLOT1 was significantly decreased in both mRNA and
protein level after the over-expression of miR-182-5p
(Figure 4D and E).
We then carried out luciferase reporter assays to ver-
ify a direct interaction between miR-182-5p and the 3′
UTR of FLOT1. The 3′-UTR of FLOT1 mRNA has 3
putative miR-182-5p binding sites (Figure 4B). We
cloned the 3′-UTR into down-stream of firefly lucifer-
ase of pmirGLO Dual-Luciferase miRNA Target Ex-
pression Vector. Cotransfected of either miR-182-5p or
NC and luciferase reporter constructs comprising 3′-
UTR was conducted. HEK 293 T cells transiently trans-
fected with the 3′- UTR-reporter and miR-182-5p
showed significantly decreased relative luciferase activ-
ity when compared with NC. However, the luciferase
activity of the control vector was unaffected by the sim-
ultaneous transfection of miR-182-5p (Figure 4C).Repression of FLOT1 plays essential roles in miR-182-5p-
supressed proliferation of RCC cells
To determine whether the downregulation of FLOT1 was
involved in miR-182-5p-mediated suppression of prolifer-
ation, we first analyzed the functions of FLOT1 in RCC
cells, which had not been previously reported. As shown
in Figure 5A and Additional file 6: Figure S6, the transfec-
tion of small interfering RNA against FLOT1 into 786-O
and Caki-1 cells led to dramatically decreased FLOT1 ex-
pression in protein and mRNA levels. Moreover, silencing
FLOT1 significantly suppressed the proliferation and
tumorigenicity of RCC cells in vitro and induced G1 arrest
(Figure 5B, C and D), which phenocopied the effects of
miR-182-5p on RCC cells. In addition, silencing FLOT1
also inhibited AKT/FOXO3a signaling. As shown in
Figure 5E, the phosphorylation levels of both FOXO3a
and AKT decreased in FLOT1-knockdown RCC cells, and
FOXO3a activity was strongly induced (Figure 5F and
Additional file 7: Figure S7). Accordingly, CCND1, CDK4,
p-Rb and E2F1 expression levels were significantly de-
creased (Figure 5E and Additional file 7: Figure S7). In
parallel, co-transfection of pFLOT1 was applied to
abrogate the FLOT1 expression inhibition by miR-182-
5p (Figure 6A). Forced FLOT1 expression partially, but
Figure 3 Overexpression of miR-182-5p inhibits the G1/S transition and cell cycle progression in RCC cells. (A) Flow cytometric analysis
of cell cycle distribution. Over-expression of miR-182-5p induced a significant accumulation of cells in G1-phase and blocks G1-S entry. (B) Western
blotting analysis of indicated proteins. (C) FOXO3a activity was strongly activated by upregulation of miR-182-5p. (D) Real-time PCR analysis of the
expression of CCND1 and CDK4 mRNA; GAPDH was used as a loading control. Error bars represent the S.D. from three independent experiments.
*P < 0.05.
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miR-182-5p (Figure 6B and C) and promoted cell viability
(Additional file 8: Figure S8).
Discussion
In recent years, emerging studies have clearly confirmed
the important roles of miRNAs in the tumorigenesis of
RCC and other malignancies. Although many studies
have characterized the miRNA signatures of RCC, the
roles of miRNA dysregulation in RCC proliferation and
tumorigenicity remain elusive. In the present study, the
miR-182-5p expression level was significantly lower in
RCC tissues compared with the corresponding non-
tumor tissues. Furthermore, gain-of-function analyses of
miR-182-5p in vitro and in vivo suggest that miR-182-5p
was able to suppress the proliferation and tumorigenicity
of RCC cells, and may serve as a tumor-suppressor gene.
The human miR-182-5p, located at chromosome 7q32
region, is transcribed from the cluster of the miR-183 fam-
ily and has been extensively researched in human cancers.
On one hand, miR-182-5p was reported to function as an
oncogene in most common types of human cancers, but
on the other hand, miR-182-5p exhibited tumor-
suppressive activity in human gastric adenocarcinoma,lung adenocarcinomas, and posterior uveal melanoma
[26-28]. MicroRNAs have been shown to frequently regu-
late numerous target genes with possible counteracting
functions. Thus, the cell context-dependent balance among
the network of directly regulated genes of miR-182-5p may
determine the biological function in a specific cancer. In
this study, we observed that the expression of miR-182-5p
was decreased in most of our RCC tissues and that
miR-182-5p may serve as a tumor-suppressor gene. Al-
though down expression of miR-182-5p has been re-
ported in several types of human cancers [26-28], little
is known about the mechanisms of its downregulation.
Thus, the first important finding of our present study is
that epigenetic modulation may be involved in the
regulation of miR-182 expression.
We have also demonstrated that the molecular mechan-
ism by which miR-182-5p inhibited RCC cell proliferation
and tumorigenicity could be attributed to, at least in part,
triggering G1-phase arrest via suppression of the AKT/
FOXO3a signaling pathway. Previous research has indi-
cated that the PI3K/AKT pathway plays an important role
in cell cycle progression through the G1 phase [37].The
activation of PI3K/AKT reduces the levels of p21Cip1 and
p27Kip1, and increases expression of CCND1 [38,39],
Figure 4 FLOT1 is a direct target of miR-182-5p. (A) Representative IHC analyses of FLOT1 expression in normal kidney tissue and RCC
specimens of three types of RCC. (B) Predicted miR-182-5p target sequences in the 3′-UTR of FLOT1. (C) miR-182-5p significantly suppressed the
luciferase activity of vector that carried 3′-UTR of FLOT1 but not control vector. (D) Western blot analysis confirmed that miR-182-5p inhibited the
endogenous expression of FLOT1. (E) FLOT1 mRNA levels decreased when miR-182-5p was up-regulated. Error bars represent the S.D. from three
independent experiments. *P < 0.05.
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PI3K/AKT effector in human cancers [34,35,40] and tran-
scriptionally regulates the above mentioned cell cycle reg-
ulators [33]. In the current study, we found that the
upregulation of miR-182-5p decreased AKT phosphoryl-
ation and significantly increased the transactivation activ-
ity of FOXO3a, suggesting that this pathway might
represent a new mechanism underlying the development
of RCC.A miRNA usually performs its specific function by de-
creasing the expression of target genes. Thus, we further
explored the possible mechanism by which miR-182-5p
could inhibit the AKT/FOXO3a signaling pathway. As a
result, FLOT1, a marker of lipid rafts, was identified as a
novel target of miR-182-5p. FLOT1 encodes a caveolae-
associated, integral membrane protein that belongs to
lipid raft family members and functions as a signaling
molecule that tethers membrane receptors linked to
Figure 5 Downregulation of FLOT1 phencopied the effect of miR-182-5p. (A) Western blot analysis showed reduction of FLOT1 protein after
siFLOT1 treatment. (B) CCK-8 assay. The relative cell viability of the siFLOT1 transfected group was significantly lower than that of NC transfected.
(C) Colony formation assay (Representative wells were presented). The colony formation rate was significantly lower for siFLOT1 treated group
compared with NC treated group. (D) Flow cytometric analysis of cell cycle distribution. Down expression of FLOT1 induced a significant accumulation of
cells in G1-phase and blocks G1-S entry. (E) Western blotting analysis of indicated proteins. (F) FOXO3a activity was strongly activated by downregulation
of FLOT1. (G) Real-time PCR analysis of the expression of CCND1 and CDK4 mRNA; GAPDH was used as a loading control. Error bars represent the S.D.
from three independent experiments. *P< 0.05.
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[41,42]. It has been reported that the silencing of FLOT1
inhibited the proliferation and tumorigenesis of breast
cancer, oral squamous cell carcinoma and esophageal
squamous cell carcinoma cells both in vitro and in vivo
[36,43,44]. Moreover, in breast cancer, esophageal squa-
mous cell carcinoma, hepatocellular carcinoma, and lung
adenocarcinoma, overexpression of FLOT1 could be used
as a valuable maker for the prediction of a poor prognosis
for patients [36,44-46]. All of these findings suggested an
oncogenic role for FLOT1 in human cancers.
Regarding RCC, Raimondo’s membrane proteomic
study suggested that FLOT1 was up-regulated in humanRCC tissues compared to para-cancer kidney tissues
[47]. However, until now, the function of FLOT1 in RCC
has not been reported. In this study, we demonstrated
that FLOT1 was overexpressed in RCC versus adjacent
non-tumor tissues and that silencing FLOT1 signifi-
cantly inhibited the proliferation and tumorigenesis of
RCC cells through regulation of the AKT/FOXO3a
pathway. Additionally, FLOT1 was directly regulated by
miR-182-5p. Ectopic overexpression of FLOT1 (without
the 3′-UTR) significantly abrogated the miR-182-
induced G1 arrest of RCC cells and promoted cell via-
bility in vitro. Taken together, these results suggest that
miR-182-5p inhibits the proliferation of RCC cells via,
Figure 6 Forced expression of FLOT1 partly rescued miR-182-5p-dependent G1 phase arrest. (A) Caki-1 cells were co-transfected with
either miR-182-5p mimics or NC oligos with pIRES-EGFP-FLOT1 or empty pIRES-EGPF vector. The expression of FLOT1 or GAPDH was detected by
Western blot analysis. (B) and (C) Forced expression of FLOT1 partly abrogated cell cycle arrest effect of miR-182-5p in Caki-1 cells. Error bars
represent the S.D. from three independent experiments. *P < 0.05.
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FLOT1. Thus, our current study reveals what we be-
lieve to be a novel upstream regulatory mechanism of
FLOT1 in cancer cells
Conclusions
Our study suggests that miR-182-5p is a potential tumor
suppressor in RCC. miR-182-5p, by targeting FLOT1,
could suppress proliferation and tumorigenesis of RCC
cells. The restoration of miR-182-5p could be a vigorous
therapeutic strategy for RCC treatment.
Materials and methods
Cell lines and cell culture
The human RCC cell lines 786-O and Caki-1 were pur-
chased from the Shanghai Institute of Cell Biology,
Shanghai, China and were cultured in RPMI 1640
medium supplemented with 10% heat-inactivated fetal
bovine serum under a humidified atmosphere of 5%
CO2 at 37°C.
Tissue samples
Twenty-five paired renal cancer tissues and adjacent
non-tumor tissues were obtained from patients undergo-
ing radical nephrectomy. The samples were collected be-
tween January 2013 and October 2013 at the First
Affiliated Hospital of Medical College, Zhejiang University
(Hangzhou, P.R. China) after informed consent and the
approval of the Ethics Committee of Zhejiang University.Clinicopathological characteristics of the patients are
presented in Supporting Additional file 9: Table S1.
Additionally, a commercial tissue microarray bearing
31 pairs of renal cell cancer and corresponding non-
tumor tissues (10 clear cell renal cell carcinoma, 11
papillary renal cell carcinoma and 10 chromophobe
renal cell carcinoma, respectively) were purchased from
Shanghai Outdo Biotech for immunohistochemical ana-
lysis of FLOT1.RNA isolation and qRT-PCR
Total RNA was extracted using RNAiso plus (Takara,
Japan) according to the manufacturer’s instructions.
Reverse transcription reactions were performed using
PrimeScript RT reagent Kit (Takara, Japan) for mRNA
detection. The resulting cDNA was quantified with the
ABI 7500 FAST real-time PCR System (Applied Biosys-
tems, Carlsbad, USA) using SYBR Green (Takara, Dalian,
China). Levels of relative expression were calculated and
quantified with the 2-ΔΔCt method after normalization
with reference to expression of GAPDH.
To detect the level of miR-182-5p, the complementary
DNA was synthesized using One Step PrimeScript
miRNA cDNA Synthesis Kit (TaKaRa, Japan), and real-
time PCR analysis was performed with the ABI 7500
FAST real-time PCR System. The expression of human
U6 small nuclear RNA was used for normalization. All
primers used were listed in Table 1.
Table 1 The oligonucleotides used in this study
Namea Sequence(5′->3′)b














aF, forward primer; R, reverse primer.
bRestriction sites are in bold.
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IHC staining was conducted as described previously
[48]. Briefly, tissue sections were dewaxed and rehy-
drated before performing antigen retrieval. The slides
were incubated with anti-ki-67 or anti-FLOT1 (Epitomics,
Burlingame, USA) overnight at 4°C, and incubated with
an HRP-conjugated secondary antibody for 1 h at room
temperature. DAB was used for color development, and
dark brown staining was considered positive. The strength
of positivity was semi-quantified by taking into account
the staining intensity and the percentage of positive cells.
Transient transfection of miRNA mimics and small
interfering RNAs
The miR-182-5p mimic, small interfering RNAs (siRNAs)
of FLOT1 and the negative control were purchased from
GenePharma (Shanghai, China). For convenience, these
are termed miR-182-5p, siFLOT1 and NC, respectively.
miRNA and siRNA transfection was carried out using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in
accordance with the manufacturer’s procedure.
Cell proliferation assay
Approximately 4 × 103 786-O cells or Caki-1 cells were
plated in each well of a 96-well plate. After an overnight
incubation, the cells were transfected with the RNAs
(miR-182-5p, siFLOT1 or NC) for 2 days. Then, the
medium was removed, and cell counting solution (WST-8,
Dojindo Laboratories, Tokyo, Japan) was added to each
well and incubated for an additional 1 h. The absorbance
of the solution was measured spectrophotometrically at
450 nm with MRX II absorbance reader (Dynex Tech-
nologies, Chantilly, VA, USA).In vitro colony formation assay
Cells were trypsinized to single cell suspensions 24 h
after transfection with 2′-O-Methyl modified duplexes
(50 nM). Then, the cells were seeded into fresh six-well
plates at 600 cells/well. After 2 weeks, the colonies were
fixed with absolute methanol and then stained with crys-
tal violet. The colonies with a diameter over 2 mm were
counted.
In vivo tumorigenicity assays
Animal studies were carried out according to institu-
tional guidelines. Male BALB/c-nude mice (4 weeks old)
were purchased from the Shanghai Experimental Animal
Center, Chinese Academy of Sciences, Shanghai, China.
Caki-1 cells (1 × 106 in 100 μl PBS) were injected subcuta-
neously into the right flank of each mouse. When palpable
tumors arose, the mice were injected intratumorally with
30 μg of Lipofectamine 2000-encapsulated miR-182-5p or
NC every 3 days for 3 weeks. Tumor size was monitored
and evaluated every 3 days. Tumor growth was monitored
by caliper measurements of the two perpendicular diame-
ters every 3 days, and the volume of the tumor was calcu-
lated with the formula V = (width2 × length × 0.52).
Cell cycle analysis by flow cytometry
Cells were collected 48 h after RNA treatment and fixed
in 75% ethanol overnight at −20°C. Then, the cells were
washed twice with PBS and followed by RNase A and
propidium iodide (50 μg/ml) treatment for 30 min.
Finally, cell cycle analyses were performed with the BD
LSRII Flow Cytometer System with FACSDiva Software
(BD Bioscience, Franklin Lakes, USA). The raw data were
analyzed by ModFit LT 3.2 software (Verity Software
House, Topsham, USA).
5-Aza-2′-deoxycytidine treatment of the 786-O and Caki-1
cell line
786-O and Caki-1 cells were treated with 5 μM 5-Aza-2′-
deoxycytidine (Sigma A3656) for 4 days. RNA was
extracted and analyzed for the expression of miR-182-5p.
DNA methylation analysis
Genomic DNA from 786-O and Caki-1 cell line and two
pairs of RCC and corresponding non-tumor tissues was
bisulfite modified and the CpG islands amplified by PCR
using the primers (forward) 5′- GTTAYGATGAGGT
TATTAGGATAGAT -3′; (reverse) 5′- ATATCCTCCAAA
CTAAACCATTC -3′. The PCR products were separated
by 3% agarose gel electrophoresis, extracted and then
cloned into the pUC18 T-vector (Sangon, China). After
bacterial amplification of the cloned PCR fragments by
standard procedures, 8 clones were subjected to DNA
sequencing (Sangon, China).
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Western blot analysis was carried out as previously
described [49] with the following appropriate primary
immunoblotting antibodies: anti-GAPDH, anti-FLOT1,
anti-E2F1, anti-CDK4, anti-FOXO3a, anti-p-FOXO3a
(phospho S253), anti-RB, anti-p-RB, anti-p-AKT (phospho
S473) (Epitomics, Burlingame, CA), anti-AKT, anti-CCN
D1 (Cell Signaling Technology, Beverly, MA).Vector construction and dual-luciferase reporter assay
The 3′-UTR of FLOT1 was cloned downstream of the lu-
ciferase reporter in the pmirGLO Dual-Luciferase miRNA
Target Expression Vector (Promega, Madison, USA) be-
tween the SacI and SalI sites and verified by sequencing.
HEK 293 T cells were plated in 24-well plates and trans-
fected with 50 nM miR-182-5p or NC and 100 ng of the
luciferase vector (pmirGLO). Cells were harvested 48 h
post-transfection. The relative luciferase activity was mea-
sured by the Dual-Glo luciferase assay kit (Promega).FLOT1 rescue experiments
The FLOT1 plasmid was constructed by inserting the hu-
man FLOT1 complementary DNA lacking the 3′-UTR
into the pIRES2-EGFP (Clontech, USA, the over-
expression clone of FLOT1 would be termed as pFLOT1).
miR-182-5p or NC was cotransfected with pFLOT1 or the
empty vector (pNull). The cells were harvested 48 h after
transfection and analyzed with subsequent Western blot-
ting and cell cycle analysis.Statistical analysis
The data were expressed as the mean ± SD. All analyses
were performed using GraphPad Prism version 5 for
Windows and a two-tailed value of P < 0.05 was consid-
ered statistically significant with Student’s t-test.Additional files
Additional file 1: Figure S1. The treatment of 786-O and Caki-1 cells
with 5-Aza apparently reduced the methylation level of this CpG island.
Error bars represent the S.D. from eight randomly chosen colonies.
Additional file 2: Figure S2. The ectopic expression of miR-182-5p was
confirmed by qRT-PCR. Error bars represent the S.D. from three independent
experiments. *P < 0.05.
Additional file 3: Figure S3. Expression levels were quantitated using
ImageJ software (Wayne Rashband); GAPDH was used as a loading
control. Error bars represent the S.D. from three independent
experiments. *P < 0.05.
Additional file 4: Figure S4. LY294002 significantly activated FOXO3a.
(A) Western blotting analysis of indicated proteins. (B) Relative FOXO3a
reporter activity was strongly activated. Error bars represent the S.D. from
three independent experiments. *P < 0.05.
Additional file 5: Figure S5. Positive strength of FLOT1 was significantly
higher in RCC tissues compared with paired non-tumor tissues. Error bars
represent the S.D. from different patients. ***P < 0.001.Additional file 6: Figure S6. Expression of FLOT1 after siFLOT1
treatment was detected by qRT-PCR. Error bars represent the S.D. from
three independent experiments. *P < 0.05.
Additional file 7: Figure S7. Expression levels were quantitated using
ImageJ software (Wayne Rashband); GAPDH was used as a loading
control. Error bars represent the S.D. from three independent
experiments. *P < 0.05.
Additional file 8: Figure S8. Forced expression of FLOT1 increase cell
viability. Error bars represent the S.D. from three independent
experiments. *P < 0.05.
Additional file 9: Table S1. Patients and tumor characteristics (n = 25).
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